OTC Products · LP-219
Chlorpheniramine maleate Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-219OTC Products
- Generic identity
- Chlorpheniramine maleateTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-219
- Generic identity
- Chlorpheniramine maleate
- Presentation
- Tablet
- Catalogue strength
- 4 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: chlorpheniramine maleate.
- Dosage form: tablet.
- Catalogue strength: 4 mg.
- Catalogue pack: blister 10 × 10 tablets.
Layer 02 · Unresolved product-specific fields
- Tablet score/coating, divisibility and release characteristics.
- Approved indication, age range and dosing schedule.
- Full excipient composition and warnings for the exact tablet.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 4 mg | Tablet | — | Blister 10 × 10 tablets | Sedation/anticholinergic warnings and administration instructions require controlled product labelling. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Chlorpheniramine maleate, often called chlorphenamine in UK references, is a first-generation H1 antihistamine. It can relieve selected allergy symptoms but commonly causes sedation and has anticholinergic effects. It differs from newer less-sedating antihistamines. A tablet’s small milligram strength does not mean that impairment or overdose risk is negligible.
Clinical context and therapeutic role
Assessment considers the type of allergic symptoms, patient age, duration and the need to avoid drowsiness. The ingredient may also appear in multi-symptom cold products, making duplication relevant. Antihistamines do not replace emergency treatment of anaphylaxis and should not delay assessment of breathing difficulty. This entry describes a single-ingredient tablet and does not promote its use as a sleep aid or establish a paediatric schedule.
Selected safety context
Drowsiness, slowed reactions, blurred vision, dry mouth, constipation and urinary difficulty can occur. Older adults may be particularly susceptible to confusion and falls. Glaucoma, prostate-related urinary problems, respiratory disease and interacting medicines require review. Alcohol and other sedatives can increase impairment. Excessive exposure can be serious, and young children may have paradoxical excitation. Severe sedation or breathing difficulty requires urgent assessment.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The source specifies chlorpheniramine maleate tablets. Verify the exact salt, excipients and tablet characteristics. Products combining a sedating antihistamine with decongestants, cough suppressants or analgesics require separate assessment and are not represented here.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
Review the allergic indication, anticholinergic and sedation burden, age, comorbidity and duplicate ingredients in other products. Confirm current local labeling.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and formula.
Approved label/leaflet with warnings, age range and administration directions.
Pack/SKU and artwork specification.
Registration/market-status evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: About chlorphenamineArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 14 May 2025; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
| MedlinePlus: ChlorpheniramineArchived source classification: US National Library of Medicine medicine reference | Source revision recorded: Last revised 15 March 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-219.
Professional enquiries
Request product-specific evidence for LP-219.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.